Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-Week Phase II Study of Advanced (F3) MASH Liver Disease

Hepion Pharmaceuticals, Inc. announced additional efficacy data for rencofilstat, its lead drug candidate for the treatment of metabolic dysfunction-associated steatohepatitis, fibrotic diseases, hepatocellular carcinoma, and other chronic diseases.
[Hepion Pharmaceuticals, Inc.]
Press Release